Last reviewed · How we verify
NCT06097039: NAFLD
Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease
trial testing abdominal U/S in Non-Alcoholic Fatty Liver Disease in 100 participants. Completed in 20 February 2024.
20 January 2024
Quick facts
| Lead sponsor | Zagazig University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 January 2023 |
| Primary completion | 20 January 2024 |
| Estimated completion | 20 February 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- abdominal U/S
- Fibroscan with Controlled Attenuated Parameter (CAP scan):
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Sponsor
Zagazig University
Who can join
18 and older, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The work investigate the role of fetuin-A in the diagnosis and assessment of the severity of non-alcoholic fatty liver disease (NAFLD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study.
Elhoseeny MM, Abdulaziz BA, Mohamed MA, Elsharaby RM, et al · · 2024 · cited 15× · PMID 39026172 · DOI 10.1186/s12876-024-03310-y
Verify or expand the search:
- PubMed search for NCT06097039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other Zagazig University trials
Trials by the same sponsor.
- NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
- NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
- NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
- NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
- NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06097039 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zagazig University
- Last refreshed: 24 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06097039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing